MBOT - NASDAQ
Microbot Medical Inc.
$1.97
-0.51%Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company, through its ViRob, TipCAT, CardioSert, and Liberty micro-robotic technologies, developing Self Cleaning Shunt for the treatment of hydrocephalus and normal pressure hydrocephalus; a disposable robot for various endovascular interventional procedures; and a multi generation pipeline portfolio. It has 42 issued/allowed patents and 23 patent applications pending worldwide. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development. Microbot Medical Inc. was founded in 2010 and is based in Hingham, Massachusetts.
At a Glance
Live SnapshotMicrobot Medical Inc. Management Team
Ms. Rachel Vaknin
Chief Financial Officer
Compensation
$257,303
Dr. Juan Diaz-Cartelle
Chief Medical Officer
Compensation
$350,000
Dr. Simon Sharon MBA, MSc
Chief Technology Officer & GM of Microbot Israel
Compensation
$415,644
Mr. Harel Gadot
Co-Founder, President, Chief Executive Officer & Chairman
Compensation
$727,338
Ms. Michal Ahuvia
Director of Operations
Naama Moav
Vice President of Human Resources
Mr. Paul Mullen
Vice President of Sales
Microbot Medical Inc. Insider Positioning
During the last 12 months, there has been no insider trading activity reported for MBOT.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
0
0.00
0
0.00
+0
+$0
9-12 Months
0
0.00
0
0.00
+0
+$0
Top Buyers
No buying activity
Top Sellers
No selling activity
Insider Activity Analysis
Net Insider Sentiment
No insider trading activity reported. This could indicate blackout periods, lack of conviction, or regulatory restrictions.
Insider Participation
No insider trading activity reported from any insiders in the past year.
SEC Filings
MBOT - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2025 N/A | April 29, 2025 | April 29, 2025 | 2025 | |
DEF 14A DEF 14A 2025 N/A | February 28, 2025 | February 28, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | November 06, 2024 | November 06, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | September 19, 2023 | September 19, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | August 08, 2022 | August 08, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | August 18, 2021 | August 18, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | July 31, 2020 | July 31, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | August 09, 2019 | August 09, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | July 26, 2018 | July 26, 2018 | 2018 | |
DEF 14A DEF 14A 2017 N/A | August 11, 2017 | August 11, 2017 | 2017 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.